CTIS2023-508054-25-01招募中1 期
NEX-22-01
anexa AB0 个研究点目标入组 9 人开始时间: 2024年3月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2DCTIS2023-508054-25-00anexa AB9
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-03Helsinn Healthcare S.A.74
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-00Helsinn Healthcare S.A.74
进行中（未招募）
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Overweight, ObesityMedDRA version: 20.0Level: PTClassification code: 10033307Term: Overweight Class: 100000004861MedDRA version: 20.0Level: PTClassification code: 10029883Term: Obesity Class: 100000004861CTIS2023-507758-34-00Rose Pharma Inc.12
进行中（未招募）
1 期
Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)Adult patients with adverse Risk Acute Myeloblastic LeukemiaCTIS2022-502585-25-00Centre Hospitalier Universitaire De Nantes12